Recent News

• 06.11.2025 - Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
• 06.10.2025 - Travere Therapeutics Launches “Play It Forward” Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
• 06.03.2025 - Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
• 05.15.2025 - Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

Recent Filings

• 05.16.2025 - EX-99.1 EX-99.1
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 8-K Current report
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities